Top Companies in the Global Balloon Catheters Market

The global balloon catheters market size was valued at USD 4.5 billion in 2023, driven by the rising prevalence of cardiovascular diseases across the globe. The market is expected to grow at a CAGR of 6.5% during the forecast period of 2024-2032, with the values likely to rise from USD 4.8 billion in 2024 to USD 8.1 billion by 2032.

A balloon catheter is a medical device that has a thin, flexible tube with an inflatable balloon at its tip. The device is inserted into the body via a small incision and the balloon is carefully inflated once it reaches the desired location. The inflation of the balloon catheter compresses the plaque and improves the blood flow. Besides angioplasty, this device is also used in stent placement and for treating peripheral artery disease.

Recent data reveals that heart disease is the leading cause of death in the United States for both men and women, with one individual dying every 33 seconds from a cardiovascular condition. Coronary artery disease (CAD) ranks as the most common type of heart disease, killing 371,506 in 2022 in the United States. Further, it is estimated that 1 in 20 adults aged 20 and above are affected by coronary artery disease. Since balloon catheters are widely used in angioplasty procedures for opening narrowed or blocked coronary arteries caused by coronary artery disease, the increasing prevalence of cardiovascular conditions is expected to fuel the market demand.

A significant market trend is the rising investment to support the development and commercialization of advanced and specialized balloon catheter technologies. For instance, in February 2023, Pennsylvania-based Cagent Vascular, Inc., the manufacturer of a novel next-generation angioplasty balloon with Serration technology, secured USD 20 million in the series C financing round led by U.S. Venture Partners and other investors. Cagent intends to use the funds to boost the commercial reach of its Serranator balloon catheter, which is already utilized in 10,000 cases to treat peripheral artery disease. Such substantial investments in the market are likely to accelerate the advancement in balloon catheter technology.

The market benefits from the rising technological advancements in balloon catheter systems, leading to the introduction of more effective and patient-friendly products. The development of high-pressure non-compliant balloons that can maintain their shape even under high pressure is a key innovation in the market. Additionally, manufacturers are focusing on introducing specialty balloons with certain coatings or materials that reduce friction or the risk of puncturing.

Top Companies Leading the Global Balloon Catheters Market in 2024

1.    Medtronic

Medtronic plc, a global leader in medical technology, has a prominent presence in the market. The company is focused on developing cardiovascular devices including balloon catheters that address the evolving needs of complex cardiovascular procedures. Medtronic's advanced balloon catheter technologies such as drug-coated balloons help in reducing the risk of restenosis (recurrence of narrowing of a blood vessel). Some of its key products include Euphora™ semicompliant balloon dilatation catheter, Sprinter™ Legend™ 1.25 SuperCrosser semicompliant balloon dilatation catheter, and Sprinter™ over-the-wire semicompliant balloon cathet er. Medtronic's specialized product NC Euphora™ noncompliant balloon dilatation catheter relies on Euphora technology to deliver controlled, high-pressure performance.

2.    Boston Scientific Corporation

Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, significantly contributes to the balloon catheter market growth. The company’s predilatation balloon catheter device Emerge™ PTCA Dilatation Catheter is widely used for challenging coronary artery procedures. Boston Scientific heavily invests in continuous innovation of its products, with special emphasis on improving the performance and deliverability of its balloon catheter. Further, in March 2024, Boston Scientific’s Agent drug-coated balloon received US Food and Drug Administration (FDA) approval to treat coronary in-stent restenosis (ISR), obstruction or narrowing of a stented vessel.

3.    Abbott

Abbott Laboratories, a leading medical device company developing solutions for cardiovascular health, chronic pain, diagnostic testing, and diabetes management, among others, is a key player in the market. Abbott specializes in the development of drug-eluting balloon technology that prevents restenosis by releasing therapeutic agents directly to the treatment site. Its product Armada™ Balloon Catheter is designed for the treatment of peripheral artery disease. Armada 35 balloon dilation catheter  comes in different balloon lengths (20 mm to 250 mm) and diameters (3 mm to 14 mm) to accommodate different vessel sizes.

4.    Spectrum Plastics Group

Spectrum Plastics Group is a leading supplier of high-quality components and custom-designed balloon catheter products in the market. The company offers custom balloon manufacturing services, including the production of compliant, non-compliant, and semi-compliant balloons. Spectrum Plastics is known for employing Apollo® Balloon Tubing and Earnan® Balloon Technology to develop medical balloon catheters for various clinical applications. The company is actively engaged in enhancing the performance and reliability of its balloon catheter products and also invests in new manufacturing technologies that enable the production of more complex and precise balloon catheter components.

5.    Biotronik

German-based Biotronik is a multi-national cardiovascular biomedical research and technology company that is known for its innovative balloon catheter offerings directed at improving clinical outcomes in coronary and peripheral interventions. The company focuses on the development of drug-coated balloons that ensure mechanical and pharmacological benefits to the patient. Biotronik also invests in optimizing the design of its balloon catheters to make them more effective in treating complex vascular pathways. Its Passeo-35 Xeo percutaneous transluminal angioplasty (PTA) balloon catheter, which received approval for European market release in 2020 is known for its excellent traceability, improved pusability, and crossability across a wide range of sizes.